Company intelligence / Profile preview

CBD Biotech

Kunming, Yunnan, China

Ownership: Private
Development stage: Other

Overview

Yunnan CBD Biotech Co., Ltd., a subsidiary of the Hansma Group, is a leading Chinese biotechnology company specializing in the industrial hemp industry. It was the first company in China to receive a license for industrial hemp processing and operates a large-scale, GMP-compliant extraction facility in Yunnan Province. The company focuses on the research, development, and production of high-purity cannabidiol (CBD) and other hemp-derived cannabinoids for use in pharmaceuticals, cosmetics, and food products. CBD Biotech leverages advanced extraction and purification technologies to provide high-quality ingredients and R&D services to global partners in the life sciences sector.

Therapeutic areas: PsychiatryImmunologyNeurologyDermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on CBD Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBD Biotech.

Explore the full profile